1:28 PM
Sep 05, 2018
 |  BC Extra  |  Company News

Chi-Med scores a China first with approval of fruquintinib

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said China's National Medical Products Administration (NMPA) approved Elunate fruquintinib to treat metastatic colorectal cancer (mCRC). According to Chi-Med, the drug is the first China-discovered and developed product for an oncology indication to receive unconditional approval based on a randomized clinical trial.

The drug, a small molecule inhibitor of VEGF receptors 1, 2 and 3, is indicated to treat mCRC patients who have failed at least two prior systemic antineoplastic therapies with or without prior use of anti-VEGF or anti-EGFR therapies.

Chi-Med was co-founded in 2000 by Samantha Du, who is founder, Chairman...

Read the full 473 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >